close
Legal

France chooses companies to provide free medical cannabis on a trial basis

Export Cannabis France

5 companies won the tender for the free supply of cannabis to around 3000 patients in France for two years

The French Agency for the Safety of Medicines and Health Products (ANSM) has selected companies that will provide the French medical cannabis pilot programl Intended to provide free products to patients participating in the trial.

3000 patients will receive free medical cannabis

Cannabis companies from Australia, Canada, Israel and the United Kingdom, in partnership with French pharmaceutical distributors, will provide the products to 3000 patientss maximum and will not receive money for the supply of medical cannabis.

The French authorities have selected main suppliers, as well as substitute suppliers to cover any shortfalls.

The list of suppliers includes:

  • Althea, based in Australia (one lot as a surrogate) and Little Green Pharma (two lots as a primary supplier and one lot as a surrogate).
  • Aurora Cannabis, based in Canada (three lots as primary supplier) and Tilray (two lots as primary supplier and two lots as substitute).
  • Panaxia, based in Israel (two lots as main supplier and two lots as substitute).
  • Emmac Life Sciences, based in the United Kingdom (two replacement lots).

Candidates were judged on product, manufacturing and supply criteria.

Neither the government nor the patients will have to pay for the medical marijuana dispensed to them by the selected companies.

The participating companies have no guarantee that they will remain suppliers in the event that France expands access to medical cannabis after the experiment.

However, "with hundreds of patients already treated (at the end of the experiment) and doctors used to prescribing their products, it is probably a commercial advantage," said Nicolas Authier, university professor and chairman of the committee. ANSM scientist on medical cannabis, last October.

Cannabis products will only be used as a last resort and must meet pharmaceutical grade standards.

Only patients who meet certain conditions will be allowed to participate in the trial.

"Distance learning for healthcare professionals should begin at the end of February and the first prescriptions before March 31," Authier told MJBizDaily.

Here is the full list of suppliers and their distribution partners:

Dominant THC

Lot 1.1: Flower containing more than 8% THC and less than 1% CBD.

Main supplier: Aurora in partnership with Ethypharm.
Substitute: Tilray in partnership with Medipha Sante.
Lot 1.2: Sublingual oil containing more than 5 milligrams of THC per milliliter and less than one milligram of CBD per milliliter.

Main supplier: Tilray in partnership with Medipha Sante.
Substitute: Panaxia in partnership with Neuraxpharm France.
Lot 1.3: Oral oils containing more than 5 milligrams of THC per milliliter and less than 1 milligram of CBD per milliliter.

Main supplier: Panaxia in partnership with Neuraxpharm France.
Substitute: Emmac Life Sciences in partnership with Boiron.

Balanced THC and CBD:

Lot 2.1: Flower with more than 5% THC and 5% CBD.

Main supplier: Aurora in partnership with Ethypharm.
Substitute: Tilray in partnership with Medipha Sante.
Lot 2.2: Sublingual oil containing more than 5 milligrams of THC and 5 milligrams of CBD per milliliter.

Main supplier: Tilray in partnership with Medipha Sante.
Substitute: Little Green Pharma in partnership with Intsel Chimos.
Lot 2.3: Oral oils containing more than 5 milligrams of THC and 5 milligrams of CBD per milliliter.

Main supplier: Panaxia in partnership with Neuraxpharm.
Substitute: Emmac Life Sciences in partnership with Boiron.

Dominant CBD:

Lot 3.2: sublingual oil containing less than 1 milligram of THC per milliliter and more than 5 milligrams of CBD per milliliter.

Main supplier: Little Green Pharma in partnership with Intsel Chimos.
Substitute: Althea in partnership with Bouchara Recordati Laboratories.
Lot 3.4: Flower containing less than 5% THC and more than 5% CBD.

Main supplier: Aurora in partnership with Ethypharm.
No substitute.
Lot 3.5: Sublingual oil containing less than 5 milligrams of THC per milliliter and more than 5 milligrams of CBD per milliliter.

Main supplier: Little Green Pharma in partnership with Intsel Chimos.
Substitute: Panaxia in partnership with Neuraxpharm France.

The CBD-dominant category initially had six lots in the application process, but suppliers were only selected for the three lots mentioned above.

Tags : AustraliaCanadaFranceIsraelMedicalUK
Weed-master

The author Weed-master

Weed media broadcaster and communications manager specializing in legal cannabis. Do you know what they say? knowledge is power. Understand the science behind cannabis medicine, while staying up to date with the latest health related research, treatments and products. Stay up to date with the latest news and ideas on legalization, laws, political movements. Discover tips, tricks and how-to guides from the most seasoned growers on the planet as well as the latest research and findings from the scientific community on the medical qualities of cannabis.